DK3285809T3 - Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. - Google Patents

Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. Download PDF

Info

Publication number
DK3285809T3
DK3285809T3 DK16719655T DK16719655T DK3285809T3 DK 3285809 T3 DK3285809 T3 DK 3285809T3 DK 16719655 T DK16719655 T DK 16719655T DK 16719655 T DK16719655 T DK 16719655T DK 3285809 T3 DK3285809 T3 DK 3285809T3
Authority
DK
Denmark
Prior art keywords
immunction
infections
inhibitors
cancer
treatment
Prior art date
Application number
DK16719655T
Other languages
English (en)
Inventor
Kevin R Webster
Vikas Goel
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Application granted granted Critical
Publication of DK3285809T3 publication Critical patent/DK3285809T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Genetics & Genomics (AREA)
DK16719655T 2015-04-20 2016-04-15 Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. DK3285809T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562150140P 2015-04-20 2015-04-20
US201562260917P 2015-11-30 2015-11-30
PCT/US2016/027870 WO2016172010A1 (en) 2015-04-20 2016-04-15 Inhibitors of immune checkpoint modulators for use in treating cancer and infections

Publications (1)

Publication Number Publication Date
DK3285809T3 true DK3285809T3 (da) 2019-11-18

Family

ID=55861220

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16719655T DK3285809T3 (da) 2015-04-20 2016-04-15 Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.

Country Status (9)

Country Link
US (2) US10702526B2 (da)
EP (1) EP3285809B1 (da)
JP (1) JP6681919B2 (da)
KR (2) KR20180004740A (da)
CN (1) CN107750167B (da)
AU (1) AU2016252038B2 (da)
CA (1) CA2982984C (da)
DK (1) DK3285809T3 (da)
WO (1) WO2016172010A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3285809B1 (en) 2015-04-20 2019-09-11 eFFECTOR Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US10112955B2 (en) * 2015-10-29 2018-10-30 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
BR112018008711A2 (pt) * 2015-10-29 2018-10-30 Effector Therapeutics Inc compostos de pirrolo-, pirazolo-, imidazo-pirimidina e piridina que inibem mnk1 e mnk2
WO2017087808A1 (en) * 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
JP7178906B2 (ja) 2016-05-19 2022-11-28 ザ ジェネラル ホスピタル コーポレイション ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
TW201831479A (zh) * 2017-01-20 2018-09-01 德商拜耳製藥公司 經取代二氫咪唑并吡啶二酮
JP6664684B1 (ja) * 2017-02-07 2020-03-13 学校法人 埼玉医科大学 がん免疫療法の臨床効果を予測する免疫学的バイオマーカー
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
CA3053493A1 (en) 2017-02-14 2018-08-23 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
EP3391907B8 (en) 2017-04-20 2020-03-04 iOmx Therapeutics AG Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
US10233226B2 (en) * 2017-06-21 2019-03-19 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
WO2019079369A1 (en) * 2017-10-19 2019-04-25 Effector Therapeutics, Inc. BENZIMIDAZOLE INDOLE INHIBITORS OF MNK1 AND MNK2
US11407831B2 (en) * 2017-10-30 2022-08-09 Ube Industries, Ltd. Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent
CN111918667A (zh) * 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法
CN109266731A (zh) * 2018-08-23 2019-01-25 窦帅杰 Tim-3与NF90的相互作用在预防或治疗病毒感染产品中的应用
CN113286592A (zh) 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US20220088231A1 (en) * 2018-12-03 2022-03-24 Fusion Pharmaceuticals Inc. Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
WO2020127369A1 (en) * 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
TW202035702A (zh) 2019-02-20 2020-10-01 學校法人埼玉醫科大學 評價藉由放射線治療之抗腫瘤免疫效果之末梢血液生物標記
CN109833480B (zh) * 2019-03-22 2021-09-07 中国科学院上海巴斯德研究所 靶向nk细胞免疫检查点治疗感染性疾病的方法
US20200318200A1 (en) 2019-04-02 2020-10-08 The Brigham And Women's Hospital, Inc. Methods for Identifying Progression of a Primary Melanoma
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2021003194A1 (en) * 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Eif4e inhibitors for use as immune checkpoint modulators and related methods
TW202114681A (zh) 2019-07-02 2021-04-16 美商ｅＦＦＥＣＴＯＲ醫療公司 轉譯抑制劑及其用途
US20220257571A1 (en) * 2019-07-10 2022-08-18 Funpació Hospital Universitari Vall D'hebron - Institut De Recerca Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations
AU2020325027A1 (en) * 2019-08-05 2022-03-03 The Board Of Trustees Of The Leland Stanford Junior University Manipulation and use of antigen-specific regulatory T cells
CN114555820A (zh) * 2019-09-05 2022-05-27 帕姆基因有限公司 用于预测非小细胞肺癌患者对pd-1或pd-l1免疫检查点抑制剂的响应的激酶活性签名
WO2021095835A1 (en) 2019-11-13 2021-05-20 Taiho Pharmaceutical Co., Ltd. Novel salt of terphenyl compound
FI4063364T3 (fi) 2019-11-18 2024-11-19 Jumbo Drug Bank Co Ltd Mnk-inhibiittoreina toimivat pyrrolotriatsiiniyhdisteet
CA3165384A1 (en) * 2019-12-19 2021-06-24 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
CN115120598A (zh) * 2021-03-29 2022-09-30 药捷安康(南京)科技股份有限公司 多激酶抑制剂的联合应用
BR112023023189A2 (pt) 2021-05-08 2024-01-30 Jumbo Drug Bank Co Ltd Composto, formas cristalinas a e b de um composto, método de preparação para a forma cristalina a de um composto, e, uso do composto, das formas cristalinas a e b e de formas cristalinas preparadas pelo método
CN114315774B (zh) * 2022-01-04 2023-05-09 山东第一医科大学(山东省医学科学院) Psf蛋白抑制剂、药物组合物及其应用
WO2024017229A1 (zh) * 2022-07-19 2024-01-25 成都嘉葆药银医药科技有限公司 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
CA2655799A1 (en) 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2010036404A2 (en) 2008-05-09 2010-04-01 University Of Maryland, Baltimore Novel retinamide retinoic acid metabolism blocking agents
UY32072A (es) 2008-08-26 2010-03-26 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmacéuticas
WO2010055072A2 (en) * 2008-11-12 2010-05-20 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating a mnk
US20140288069A1 (en) 2011-05-17 2014-09-25 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
WO2012163942A1 (en) 2011-06-01 2012-12-06 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
WO2012175591A1 (en) 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
MX368257B (es) * 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
CA2849345A1 (en) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
CN104114559B (zh) 2011-12-12 2016-08-24 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
ES2663609T3 (es) 2012-03-29 2018-04-16 Bayer Intellectual Property Gmbh Imidazopiridazinas amino-sustituidas
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
EP2834245B1 (en) 2012-04-04 2017-12-13 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
HK1206723A1 (en) 2012-05-21 2016-01-15 Bayer Pharma Aktiengesellschaft Thienopyrimidines
EP2852593A1 (en) 2012-05-21 2015-04-01 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
CA2873967A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014048869A1 (en) 2012-09-26 2014-04-03 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
US20150218173A1 (en) 2012-09-26 2015-08-06 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
EP2917185B1 (en) 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
GB2508652A (en) 2012-12-07 2014-06-11 Agency Science Tech & Res Heterocyclic piperazine derivatives
WO2014118135A1 (en) 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
CA2899662A1 (en) 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
JP2016514087A (ja) 2013-02-01 2016-05-19 バイエル・ファルマ・アクティエンゲゼルシャフト 置換チエノピリミジンおよびその薬学的使用
HK1212699A1 (zh) 2013-02-20 2016-06-17 拜耳医药股份公司 作为mknk1抑制剂的取代的咪唑并[1，2-b]哒嗪类化合物
WO2014135480A1 (en) 2013-03-06 2014-09-12 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
ES2822665T3 (es) * 2013-05-31 2021-05-04 Merck Sharp & Dohme Terapias de combinación para el cáncer
CA2914525C (en) 2013-06-28 2021-07-27 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
JP2016527216A (ja) 2013-07-08 2016-09-08 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロピリジン
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
EP3285809B1 (en) 2015-04-20 2019-09-11 eFFECTOR Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections

Also Published As

Publication number Publication date
KR20180004740A (ko) 2018-01-12
JP2018513172A (ja) 2018-05-24
AU2016252038B2 (en) 2021-08-12
CN107750167B (zh) 2021-05-25
EP3285809B1 (en) 2019-09-11
NZ736852A (en) 2024-07-26
CN107750167A (zh) 2018-03-02
KR102891799B1 (ko) 2025-11-26
US10702526B2 (en) 2020-07-07
JP6681919B2 (ja) 2020-04-15
AU2016252038A1 (en) 2017-11-02
KR20240038145A (ko) 2024-03-22
EP3285809A1 (en) 2018-02-28
CA2982984A1 (en) 2016-10-27
US20160303124A1 (en) 2016-10-20
CA2982984C (en) 2023-10-17
US20210046074A1 (en) 2021-02-18
WO2016172010A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3331900T3 (da) Peptider og kombination af peptider til anvendelse ved immunterapi mod prostatacancer og andre cancere
IL280863A (en) Autotaxin inhibitors and uses thereof
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3227237T3 (da) Indretning og anvendelse deraf til uv-bearbejdning af fluider
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3521289T3 (da) Mnk-inhibitorer og fremgangsmåder forbundet dermed
DK3842429T3 (da) Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
DK3256218T3 (da) Kdm1a-hæmmer og anvendelse deraf i terapi
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3122358T3 (da) Kombinationer af fgfr- og cmet-hæmmere til cancerbehandling
DK4339615T3 (da) Anti-PD-1-antistof til anvendelse i behandlingen af kræft
IL261047A (en) Taf1 inhibitors for the therapy of cancer
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3113782T3 (da) Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3380086T3 (da) Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft